Abstract 29P
Background
Colorectal cancer (CRC) is one of the most common cancers worldwide. In particular, the yearly mortality emphasizes the limited spectrum of treatment possibilities. The tumor microenvironment with its relevant influence on malignant tumor initiation, progression and chemoresistance represents a promising target for cancer therapeutics. Especially cancer-associated fibroblasts (CAFs) are of importance in carcinogenesis as they are involved in tumorigenesis, metastasis, inflammatory responses, and extracellular matrix changes. Based on preliminary data, we found upregulated expression of INHBA, a gene encoding for the βA subunit of the TGFβ superfamily members Activin A, Activin AB and Inhibin A, in the stromal compartment of human CRC. Therefore, we wanted to investigate the autocrine and paracrine functional consequences of CAF-secreted Activin A in CRC.
Methods
We knocked down INHBA in primary patient-derived CAFs and used in vitro 3D collagen gel assays, flow cytometry, immunofluorescence, secretome analysis and Western blotting to check the autocrine effects of Activin A on CAFs. Regarding the paracrine impact on tumor cells and immune cells, we employed 3D co- and triple-culture collagen gel assays to determine the impact of CAF-derived Activin A. Here, we focused on proliferation, apoptosis and invasion levels of tumor cells as well as on monocyte differentiation, myeloid cell plasticity and T-cell activation.
Results
Our data demonstrate that CAFs expressing INHBA show a pro-proliferative, pro-motile and pro-contractile phenotype. Furthermore, the secretome and plasticity of CAFs were notably modified by the INHBA knockdown. Additionally, CAF-derived Activin A seems to influence various aspects of tumor progression and the plasticity of immune cells.
Conclusions
Together, our results indicate key functions of CAF-derived Activin A in CRC progression suggesting a potential novel therapeutic target.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Austrian Academy of Sciences.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
36P - Molecular assessment of clinical antitumour therapeutics utilising established pancreatic ductal adenocarcinoma patient-derived models
Presenter: Young-Ah Suh
Session: Poster session 09
37P - Nischarin can be a target for stromal normalisation in pancreatic ductal adenocarcinoma
Presenter: Jelena Grahovac
Session: Poster session 09
38P - Effects of antiemetics on zolbetuximab-induced gastric injury and emesis frequency in ferrets
Presenter: Jane Weng
Session: Poster session 09
39P - Casein kinase 2 modulates epithelial–mesenchymal transition through helicobacter pylori CagA-dependent pathway in gastric cancer cells
Presenter: SODAM LEE
Session: Poster session 09
40P - Bioinformatic evaluation of the transcriptomic and immunologic profile of prostate tumors with high expression of kallikrein-2
Presenter: Irene Moreno
Session: Poster session 09
42P - Developing a photodynamic therapy strategy targeted to endometrial cancer stem cells
Presenter: Beatriz Serambeque
Session: Poster session 09
43P - Looking for therapeutic targets on the proteome profile of endometrial cancer stem cells
Presenter: Mafalda Laranjo
Session: Poster session 09
44P - PAUF as a target for treatment of high PAUF-expressing ovarian cancer
Presenter: Junghyun Cho
Session: Poster session 09
45P - Therapeutic potential of ISM8207: A novel QPCTL inhibitor, in triple-negative breast cancer and B-cell non-Hodgkin lymphoma
Presenter: Sujata Rao
Session: Poster session 09